Functional dairy products for gastrointestinal infections and dysfunction

Functional Dairy Products: Second Edition

Volumn 2, Issue , 2007, Pages 63-89

  Myllyluoma, E ^a,b   Kajander, K ^a,b   Saxelin, M ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b VALIO LTD   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902570360     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1533/9781845693107.1.63     Document Type: Chapter

References (165)

1. Aiba Y., Suzuki N., Kabir A.M., Takagi A., Koga Y. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol 1998, 93(11):2097-2101.
2. Armuzzi A., Cremonini F., Ojetti V., Bartolozzi F., Canducci F., Candelli M., Santarelli L., Cammarota G., De Lorenzo A., Pola P., Gasbarrini G., Gasbarrini A. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 2001, 63(1):1-7.
3. Armuzzi A., Cremonini F., Bartolozzi F., Canducci F., Candelli M., Ojetti V., Cammarota G., Anti M., De Lorenzo A., Pola P., Gasbarrini G., Gasbarrini A. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001, 15(2):163-169.
4. Arvola T., Laiho K., Torkkeli S., Mykkänen H., Salminen S., Maunula L., Isolauri E. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhoea in children with respiratory infections: a randomized study. Pediatrics 1999, 104(5):e64.
5. Atherton J. Helicobacter pylori virulence factors. Br Med Bull 1998, 54:105-120.
6. Ballongue J., Schumann C., Quignon P. Effects of lactulose and lactitol on colonic microflora and enzymatic activity. Scand J Gastroenterol Suppl 1997, 222:41-44.
7. Balsari A., Ceccarelli A., Dubini F., Fesce E., Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982, 5(3):185-194.
8. Banasaz M., Norin E., Holma R., Midtvedt T. Increased enterocyte production in gnotobiotic rats mono-associated with Lactobacillus rhamnosus GG. Appl Environm Microbiol 2002, 68(6):3031-3034.
9. Banaszkiewicz A., Szajewska H. Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. J Pediatr 2005, 146(3):364-369.
10. Bausserman M., Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 2005, 147(2):197-201.
11. Bergonzelli G.E., Granato D., Pridmore R.D., Marvin-Guy L.F., Donnicola D., Corthésy-Theulaz I.E. GroEL of Lactobacillus johnsonii La1 (NCC 533) is cell surface associated: potential role in interactions with the host and the gastric pathogen Helicobacter pylori. Infect Immun 2006, 74(1):425-434.
12. Bleser S., Brunton S., Carmichael B., Olden K., Rasch R., Steege J. Management of chronic constipation: recommendations from a consensus panel. J Fam Pract 2005, 54(8):691-698.
13. Blum S., Haller D., Pfeifer A., Schiffrin E.J. Probiotics and immune response. Clin Rev Allergy Immunol 2002, 22(3):287-309.
14. Borriello S.P. Bacteria and gastrointestinal secretion and motility. Scand J Gastroenterol 1984, 93(Suppl.):115-121.
15. Bouhnik Y., Attar A., Joly F.A., Riottot M., Dyard F., Flourie B. Lactulose ingestion increases faecal bifidobacterial counts: a randomised double-blind study in healthy humans. Eur J Clin Nutr 2004, 58(3):462-466.
16. Brigidi P., Vitali B., Swennen E., Bazzocchi G., Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001, 152(8):735-741.
17. Brzozowski T., Konturek P.C., Mierzwa M., Drozdowicz D., Bielanski W., Kwiecien S., Konturek S.J., Pawlik W.W., Hahn E.G. Effect of probiotics and triple eradication therapy on the cyclooxygenase (COX)-2 expression, apoptosis, and functional gastric mucosal impairment in Helicobacter pylori-infected Mongolian gerbils. Helicobacter 2006, 11:10-20.
18. Canducci F., Armuzzi A., Cremonini F., Cammarota G., Bartolozzi F., Pola P., Gasbarrini G., Gasbarrini A. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000, 14(12):1625-1629.
19. Cats A., Kuipers E.J., Bosschaert M.A., Pot R.G., Vandenbroucke-Grauls C.M., Kusters J.G. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther 2003, 17(3):429-435.
20. Cesena C., Morelli L., Alander M., Siljander T., Tuomola E., Salminen S., Mattila-Sandholm T., Vilpponen-Salmela T., Von Wright A. Lactobacillus crispatus and its nonaggregating mutant in human colonization trials. J Dairy Sci 2001, 84(5):1001-1010.
21. Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004, 20(Suppl 7):31-39.
22. Cheng A.C., Mcdonald J.R., Thielman N.M. Infectious diarrhea in developed and developing countries. J Clin Gastroenterol 2005, 39:757-773.
23. Cherbut C., Aube A.C., Blottiere H.M., Galmiche J.P. Effects of short-chain fatty acids on gastrointestinal motility. Scand J Gastroenterol Suppl 1997, 222:58-61.
24. Chouraqui J.P., Van Egroo L.D., Fichot M.C. Acidified milk formula supplemented with Bifidobacterium lactis: impact on infant diarrhea in residential care settings. J Pediatr Gastroenterol Nutr 2004, 38:288-292.
25. Coconnier M.H., Lievin V., Hemery E., Servin A.L. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol 1998, 64(11):4573-4580.
26. Collado M.C., González A., González R., Hernández M., Ferrús M.A., Sanz Y. Antimicrobial peptides are among the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori. Int J Antimicrob Agents 2005, 25:385-391.
27. Correa N.B., Peret Filho L.A., Penna F.J., Lima F.M., Nicoli J.R. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol 2005, 39:385-389.
28. Corthésy B., Boris S., Isler P., Grangette C., Mercenier A. Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis. J Infect Dis 2005, 192(15):1441-1449.
29. Cremonini F., Di Caro S., Covino M., Armuzzi A., Gabrielli M., Santarelli L., Nista E.C., Cammarota G., Gasbarrini G., Gasbarrini A. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002, 97(11):2744-2749.
30. Cremonini F., Di Caro S., Nista E.C., Bartolozzi F., Capelli G., Gasbarrini G., Gasbarrini A. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002, 16:1461-1467.
31. Cruchet S., Obregon M.C., Salazar G., Diaz E., Gotteland M. Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children. Nutrition 2003, 19:716-721.
32. De Keersmaecker S.C.J., Verhoeven T.L.A., Desair J., Marchal K., Vanderleyden J., Nagy I. Strong antimicrobial activity of Lactobacillus rhamnosus GG against Salmonella typhimurium is due to accumulation of lactic acid. FEMS Microbiol Lett 2006, 259:89-96.
33. Deguchi Y., Matsumoto K., Ito A., Watanuki M. Effects of β 1-4 galacto-oligosaccharides administration on defecation of healthy volunteers with constipation tendency' [in Japanese]. Jpn J Nutr 1997, 55:13-22.
34. Dendukuri N., Costa V., Mcgregor M., Brophy J.M. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005, 173:167-170.
35. Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E. AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123(6):2108-2131.
36. D'souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002, 324:1361.
37. Ezendam J., Van Loveren H. Probiotics: immunomodulation and evaluation of safety and efficacy. Nutr Rev 2006, 64(1):1-14.
38. Felley C., Michetti P. Probiotics and Helicobacter pylori. Best Pract Res Clin Gastroenterol 2003, 17(5):785-791.
39. Felley C.P., Corthesy-Theulaz I., Rivero J.L., Sipponen P., Kaufmann M., Bauerfeind P., Wiesel P.H., Brassart D., Pfeifer A., Blum A.L., Michetti P. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol 2001, 13(1):25-29.
40. Focareta A., Paton J.C., Morona R., Cook J., Paton A.W. A recombinant probiotic for treatment and prevention of cholera. Gastroenterol 2006, 130(6):1688-1695.
41. Freitas M., Tavan E., Cayuela C., Diop L., Sapin C., Trugnan G. Host-pathogens cross-talk. Indigenous bacteria and probiotics also play the game. Biol Cell 2003, 95:503-506.
42. Gade J., Thorn P. Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand J Prim Health Care 1989, 7(1):23-26.
43. Gadewar S., Fasano A. Current concepts in the evaluation, diagnosis and management of acute infectious diarrhea. Curr Opin Pharmacol 2005, 5:559-565.
44. Gill H.S., Rutherfurd K.J. Immune enhancement conferred by oral delivery of Lactobacillus rhamnosus HN001 in different milk-based substrates. J Dairy Res 2001, 68(4):611-616.
45. Go M. Natural history and epidemiology of Helicobacter pylori infection. Alimet Pharmacol Ther 2002, 16(Suppl 1):3-15.
46. Gotteland M., Poliak L., Cruchet S., Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Pediatr 2005, 94:1747-1751.
47. Gotteland M., Brunser O., Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori. Aliment Pharmacol Ther 2006, 23(8):1077-1086.
48. Guandalini S., Pensabene L., Abu Zikri M., Amil Dias J., Gorio Casali L., Hoekstra A., Salazar De Sousa J., Sandhu B., Szajewska H., Weizman Z. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhoea: A multicenter European trial. J Pediatr Gastroenterol Nutr 2000, 30:54-60.
49. Guarino A., Berni Canani R., Spagnuolo M.I., Albano F., Di Benedetto L. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhoea. J Pediatr Gastroenterol Nutr 1997, 25:516-519.
50. Halpern G.M., Prindiville T., Blankenburg M., Hsia T., Gershwin M.E. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 1996, 91(8):1579-1585.
51. Hamilton-Miller J.M.T. Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microb Ecol Health Dis 2001, 13:212-216.
52. Hamilton-Miller J.M. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 2003, 22(4):360-366.
53. Hantschel E., Brandstatter G., Dragosics G., Hirschl A.M., Nemec H., Schutze K., Taufer M., Wurzer H. Effect of ranitidine and amoxicillin plus metronidazole on the recurrence of duodenal ulcer. New Engl J Med 1993, 328:308-312.
54. Hawrelak J.A., Whitten D.L., Myers S.P. Is Lactobacillus rhamnosus GG effective in preventing the onset of antibiotic-associated diarrhoea: a systematic review. Digestion 2005, 72:51-56.
55. Hentges D. Gut flora and disease resistance. Probiotics. The scientific basis 1992, 87-107. Chapman and Hall, London. R. Fuller (Ed.).
56. Hilton E., Kolakowski P., Smith M., Singer C. Efficacy of Lactobacillus GG as a diarrheal preventative in travelers. J Travel Med 1997, 4:41-43.
57. Hirano J., Yoshida T., Sugiyama T., Koide N., Mori I., Yokochi T. The effect of Lactobacillus rhamnosus on enterohemorrhagic Escherichia coli infection of human intestinal cells in vitro. Microbiol Immunol 2003, 47(6):405-409.
58. Høverstad T., Bjørneklett A. Short-chain fatty acids and bowel functions in man. Scand J Gastroenterol 1984, 19(8):1059-1065.
59. Hudault S., Liévin V., Bernet-Camard M.-F., Servin A. Antagonistic activity excerted in vitro and in vivo by Lactobacillus casei (strain GG) against Salmonella typhimurium C5 infection. Appl Environ Microbiol 1997, 63:513-518.
60. Hutt P., Shchepetova J., Loivukene K., Kullisaar T., Mikelsaar M. Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens. J Appl Microbiol 2006, 100:1324-1332.
61. Iarc, International Agency For Research On Cancer Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Human 1994, 61:177-240.
62. Irvine E.J., Whitehead W.E., Chey W.D., Matsueda K., Shaw M., Talley N.J., Veldhuyzen Van Zanten S.J. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006, 130(5):1538-1551.
63. Isolauri E., Juntinen M., Rautanen T., Sillanaukee P., Koivula T. A human Lactobacillus strain (Lactobacillus casei sp. strain GG) promotes recovery from acute diarrhoea in children. Pediatrics 1991, 88:90-97.
64. Isolauri E., Kaila M., Mykkänen H., Ling W.H., Salminen S. Oral bacteriotheraphy for viral gastroenteritis. Dig Dis Sci 1994, 39(12):2595-2600.
65. Johnson-Henry K.C., Mitchell D.J., Avitzur Y., Galindo-Mata E., Jones N.L., Sherman P.M. Probiotics reduce bacterial colonization and gastric inflammation in H. pylori- infected mice. Dig Dis Sci 2004, 49(7):1095-1102.
66. Kabir A.M., Aiba Y., Takagi A., Kamiya S., Miwa T., Koga Y. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut 1997, 41(1):49-55.
67. Kaila M., Isolauri E., Soppi E., Virtanen E., Laine S., Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992, 32:141-144.
68. Kajander K., Hatakka K., Poussa T., Färkkilä M., Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005, 22(5):387-394.
69. Katz J.A. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. J Clin Gastroenterol 2006, 40(3):249-255.
70. Khalif I.L., Quigley E.M., Konovitch E.A., Maximova I.D. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis 2005, 37(11):838-849.
71. Kim H.J., Camilleri M., Mckinzie S., Lempke M.B., Burton D.D., Thomforde G.M., Zinsmeister A.R. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17(7):895-904.
72. Kim H.J., Vazquez Roque M.I., Camilleri M., Stephens D., Burton D.D., Baxter K., Thomforde G., Zinsmeister A.R. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005, 17(5):687-696.
73. King T.S., Elia M., Hunter J.O. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998, 352(9135):1187-1189.
74. Kleessen B., Sykura B., Zunft H.J., Blaut M. Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am J Clin Nutr 1997, 65(5):1397-1402.
75. Koebnick C., Wagner I., Leitzmann P., Stern U., Zunft H.J. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 2003, 17(11):655-659.
76. Leahy S.C., Higgins D.G., Fitzgerald G.F., Van Sinderen D. Getting better with bifidobacteria. J Appl Microbiol 2005, 98:1303-1315.
77. Lee D.J., Drongowski R.A., Coran A.G., Harmon C.M. Evaluation of probiotic treatment in a neonatal animal model. Pediatr Surg Int 2000, 16(4):237-242.
78. Lee M.H., Roussel Y., Wilks M., Tabaqchali S. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine 2001, 19(28-29):3927-3935.
79. Lee Y.K., Puong K.Y. Competition for adhesion between probiotics and human gastrointestinal pathogens in the presence of carbohydrate. Br J Nutr 2002, 88(Suppl 1):101-108.
80. Ling W.H., Hänninen O., Mykkänen H., Heikura M., Salminen S., Von Wright A. Colonization and fecal enzyme activities after oral Lactobacillus GG administration in elderly nursing home residents. Ann Nutr Metab 1992, 36(3):162-166.
81. Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology 2006, 130(5):1480-1491.
82. Lorca G.L., Wadström T., Valdez G.F., Ljungh Å Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr Microbiol 2001, 42(1):39-44.
83. Mack D.R., Michail S., Wei S., Mcdougall L., Hollingsworth M.A. Probiotics inhibit enteropathogenis E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999, 276:G941-950.
84. Madden J.A.J. The intestinal microbiota and probiotics in irritable bowel syndrome. Scand J Nutr 2004, 48:32-36.
85. Madden J.A.J., Plummer S.F., Tang J., Garaiova I., Plummer N.T., Herbison M., Hunter J.O., Shimada T., Cheng L., Shirakawa T. Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: A double-blind, placebo-controlled pilot study. Int Immunopharmacol 2005, 5:1091-1097.
86. Majamaa H., Isolauri E., Saxelin M., Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroent Nutr 1995, 20:333-338.
87. Malfertheiner P., Mégraud F., O'morain C., Hungin S., Jones R., Axon A., Graham D., Tytgatt G., The European Helicobacter Study Group Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002, 16:167-180.
88. Malinen E., RinttilÄ T., Kajander K., Mättö J., Kassinen A., Krogius L., Saarela M., Korpela R., Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005, 100(2):373-382.
89. Marshall B., Warren J. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1984, i:1273-1275.
90. Marshall B., Goodwin C., Warren J., Murray R., Blincow E., Blackbourn S., Philips M., Waters T., Sanderson C. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988, 2:1437-1442.
91. Massi M., Ioan P., Budriesi R., Chiarini A., Vitali B., Brigidi P., Lammers K., Gionchetti P., Campieri M. The effects of probiotic bacteria on spontaneous contraction of isolated guinea pig intestine. Gastroenterology 2004, 126(4 suppl 2):A-517.
92. Mastretta E., Longo P., Laccisaglia A., Balbo L., Russo R., Mazzaccara A., Gianino P. Effect of Lactobacillus GG and breast-feeding in the prevention of rotavirus nosocomial infection. J Pediatr Gastroenterol Nutr 2002, 35(4):527-531.
93. Mättö J., Maunuksela L., Kajander K., Palva A., Korpela R., Kassinen A., Saarela M. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005, 43(2):213-222.
94. Maukonen J., Satokari R., Mättö J., Söderlund H., Mattila-Sandholm T., Saarela M. Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 2006, 55(Pt 5):625-633.
95. Mcfarland L.V. Meta-analyses of probiotics for the prevention of antibiotic associated diarrhoea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006, 101(4):812-822.
96. Meance S., Cayuela C., Raimondi A., Turchet P., Lucas C., Antoine J.-M. Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Microb Ecol Health Dis 2003, 15:15-22.
97. Meance S., Cayuela C., Turchet P., Raimondi A., Lucas C., Antoine J.-M. A fermented milk with Bifidobacterium probiotic strain DN-173 010 shortened oro-fecal gut transit time in elderly. Microb Ecol Health Dis 2001, 13:217-222.
98. Michail S., Abernathy F. Lactobacillus plantarum inhibits the intestinal epithelial migration of neutrophils induced by enteropathogenic. Escherichia coli, J Pediatr Gastroenterol Nutr 2003, 36:385-391.
99. Michetti P., Dorta G., Wiesel P.H., Brassart D., Verdu E., Herranz M., Felley C., Porta N., Rouvet M., Blum A.L., Corthesy-Theulaz I. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999, 60(3):203-209.
100. Midolo P.D., Lambert J.R., Hull R., Luo F., Grayson M.L. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol 1995, 79:475-479.
101. Montalto M., Maggiano N., Ricci R., Curigliano V., Santoro L., Di Nicuolo F., Vecchio F.M., Gasbarrini A., Gasbarrini G. Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion 2004, 69:225-228.
102. Mukai T., Asasaka T., Sato E., Mori K., Matsumoto M., Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri Lactobacillus reuteri. FEMS Immunol Med Microbiol 2002, 32(2):105-110.
103. Myllyluoma E., Veijola L., Ahlroos T., Tynkkynen S., Kankuri E., Vapaatalo H., Rautelin H., Korpela R. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy - a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 2005, 21(10):1263-1272.
104. Nam H., Ha M., Bae O., Lee Y. Effect of Weissella confusa strain PL9001 on the adherence and growth of Helicobacter pylori. Appl Environ Microbiol 2002, 68:4642-4645.
105. Newcomer A.D., Park H.S., O'brien P.C., Mcgill D.B. Response of patients with irritable bowel syndrome and lactase deficiency using unfermented acidophilus milk. Am J Clin Nutr 1983, 38(2):257-263.
106. Niedzielin K., Kordecki H., Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001, 13(10):1143-1147.
107. Niv E., Naftali T., Hallak R., Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - a double blind, placebo-controlled, randomized study. Clin Nutr 2005, 24(6):925-931.
108. Nobaek S., Johansson M.L., Molin G., Ahrne S., Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000, 95(5):1231-1238.
109. Oberhelman R.A., Gilman R.H., Sheen P., Taylor D.N., Black R.E., Cabrera L., Lescano A.G., Meza R., Madico G. A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children. J Pediatr 1999, 134:15-20.
110. Oksanen P., Salminen S., Saxelin M., Hämäläinen P., Ihantola-Vormisto A., Muurasniemi-Isoviita L., Nikkari S., Oksanen T., Pörsti I., Salminen E., Siitonen S., Stuckey H., Toppila A., Vapaatalo H. Prevention of traveller's diarrhoea by Lactobacillus GG. Ann Med 1990, 22:53-56.
111. O'mahony L., Mccarthy J., Kelly P., Hurley G., Luo F., Chen K., O'sullivan G.C., Kiely B., Collins J.K., Shanahan F., Quigley E.M. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128(3):541-551.
112. O'sullivan M.A., O'morain C.A. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000, 32(4):294-301.
113. Ouwehand A.C., Lagström H., Suomalainen T., Salminen S. Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab 2002, 46(3-4):159-162.
114. Pantoflickova D., Corthesy-Theulaz I., Dorta G., Stolte M., Isler P., Rochat F., Enslen M., Blum A.L. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther 2003, 18:805-813.
115. Pare P., Ferrazzi S., Thompson W.G., Irvine E.J., Rance L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001, 96(11):3130-3137.
116. Parsonnet J., Hansen S., Rodriguez L., Gelb A., Warnke R., Jellum E., Orentreich N., Vogelman J., Friedman G. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994, 330:1267-1271.
117. Pedone C.A., Bernabeu A.O., Postaire E.R., Bouley C.F., Reinert P. The effect of supplementation with milk fermented by Lactobacillus casei (strain DN-114 001) on acute diarrhoea in children attending day care centres. Int J Clin Pract 1999, 53:179-184.
118. Pedone C.A., Arnaud C.C., Postaire E.R., Bouley C.F., Reinert P. Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhoea. Int J Clin Pract 2000, 54:568-571.
119. Peña J.A., Versalovic J. Lactobacillus rhamnosus GG decreases TNF-α production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism. Cell Microbiol 2003, 5:277-285.
120. Pereg D., Kimhi O., Tirosh A., Orr N., Kayouf R., Lishner M. The effect of fermented yogurt on the prevention of diarrhea in a healthy adult population. Am J Infect Control 2005, 33:122-125.
121. Plummer S., Weaver M.A., Harris J.C., Dee P., Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004, 7:59-62.
122. Plummer S.F., Garaiova I., Sarvotham T., Cottrell S.L., Le Scouiller S., Weaver M.A., Tang J., Dee P., Hunter J. Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy. Int J Antimicrob Agents 2005, 26:69-74.
123. Ramkumar D., Rao S.S. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005, 100(4):936-971.
124. Resta-Lenert S., Barrett K.E. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003, 52:988-997.
125. Rosenfeldt V., Michaelsen K.F., Jakobsen M., Larsen C.N., Moller P.L., Tvede M., Weyrehter H., Valerius N.H., Paerregaard A. Effect of probiotic Lactobacillus strains on acute diarrhea in a cohort of nonhospitalized children attending day-care centers. Pediatr Infect Dis J 2002, 21:417-419.
126. Rosenfeldt V., Benfeldt E., Valerius N.H., Paerregaard A., Michaelsen K.F. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr 2004, 145(5):612-616.
127. Saavedra J.M., Bauman N.A., Oung I., Perman J.A., Yolken R.H. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994, 344:1046-1049.
128. Saavedra J.M., Abi-Hanna A., Moore N., Yolken R.H. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr 2004, 79:261-267.
129. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004, 38(6 Suppl):S104-S106.
130. Sakamoto I., Igarashi M., Kimura K., Takagi A., Miwa T., Koga Y. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother 2001, 47(5):709-710.
131. Sazawal S., Dhingra U., Sarkar A., Dhingra P., Deb S., Marwah D., Menon V.P., Kumar J., Black R.E. Efficacy of milk fortified with a probiotic Bifidobacterium lactis (DR-10TM) and prebiotic galacto-oligosaccharides in prevention of morbidity and on nutritional status. Asia Pac J Clin Nutr 2004, 13:S28.
132. Sazawal S., Hiremath G., Dhingra U., Malik P., Deb S., Black R.E. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis 2006, 6(6):374-382.
133. Sen S., Mullan M.M., Parker T.J., Woolner J.T., Tarry S.A., Hunter J.O. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002, 47(11):2615-2620.
134. Servin A.L. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 2004, 28:405-440.
135. Sgouras D., Maragkoudakis P., Petraki K., Martinez-Gonzalez B., Eriotou E., Michopoulos S., Kalantzopoulos G., Tsakalidou E., Mentis A. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain shirota. Appl Environ Microbiol 2004, 70:518-526.
136. Sgouras D.N., Panayotopoulou E.G., Martinez-Gonzalaz B., Petraki K., Michopoulos S., Mentis A. Lactobacillus johnsonii La1 attenuates Helicobacter pylori-associated gastritis and reduces levels of proinflammatory chemokines in C57BL/6 mice. Clin Diag Lab Immunol 2005, 12(12):1378-1386.
137. Sheu B.S., Wu J.J., Lo C.Y., Wu H.W., Chen J.H., Lin Y.S., Lin M.D. Impact of supplement with Lactobacillus and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002, 16:1669-1675.
138. Sheu B.S., Cheng H.C., Kao A.W., Wang S.T., Yang Y.J., Yang H.B., Wu J.J. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am J Clin Nutr 2006, 83:864-869.
139. Shornikova A.-V., Isolauri E., Burkanova L., Lukovnikova S., Vesikari T. A trial in the Karelian Republic of oral rehydration and Lactobacillus GG for treatment of acute diarrhoea. Acta Paediatr 1997, 86:460-465.
140. Si J.M., Yu Y.C., Fan Y.J., Chen S.J. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004, 10(12):1802-1805.
141. Spiller R.C. Postinfectious irritable bowel syndrome. Gastroenterology 2003, 124(6):1662-1671.
142. Surawicz C.M. Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials?. Chemotherapy 2005, 51(Suppl 1):81-89.
143. Sykora J., ValeckovÁ K., AmlerovÁ J., Siala K., Decek P., Watkins S., Varvarovska J., Stozicky F., Pazdiora P., Schawarz Effects of a specially designed fermented milk product containing probiotic Lactobacilli casei DN-114 001 and the eradication of H. pylori in children. J Clin Gastroenterol 2005, 39(8):692-698.
144. Szajewska H., Kotowska M., Mrukowicz J.Z., Armanska M., Mikolajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001, 138(3):361-365.
145. Szajewska H., Mrukowicz J.Z. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001, 33(Suppl 2):S17-25.
146. Szajewska H., Setty M., Mrukowicz J., Guandalini S. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr 2006, 42(5):454-475.
147. Teuri U., Korpela R. Galacto-oligosaccharides relieve constipation in elderly people. Ann Nutr Metab 1998, 42(6):319-327.
148. Thibault H., Aubert-Jacquin C., Goulet O. Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants. J Pediatr Gastroenterol Nutr 2004, 39:147-152.
149. Treem W.R., Ahsan N., Kastoff G., Hyams J.S. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr 1996, 23(3):280-286.
150. Tsai C.C., Huang L.F., Lin C.C., Tsen H.Y. Antagonistic activity against Helicobacter pylori infection in vitro by a strain of Enterococcus faecium TM39. Int J Food Microbiol 2004, 96:1-12.
151. Turck D., Bernet J.P., Marx J., Kempf H., Giard P., Walbaum O., Lacombe A., Rembert F., Toursel F., Bernasconi P., Gottrand F., Mcfarland L.V., Bloch K. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 2003, 37:22-26.
152. Tursi A., Brandimarte G., Giorgetti G.M., Modeo M.E. Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Med Sci Monit 2004, 10(12):662-666.
153. UNICEF/WHO Roaj Reduced osamolarity oral rehydration salts (ORS) formulation 2001.
154. Vaira D., Holton J., Ricci C., Menegatti M., Gatta L., Berardi S., Tampieri A., Miglioli M. Review article: the transmission of Helicobacter pylori from stomach to stomach. Aliment Pharmacol Ther 2001, 15(1):S33-43.
155. Van Niel C.W., Feudtner C., Garrison M.M., Christakis D.A. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002, 109:678-684.
156. Verdu E.F., Collins S.M. Irritable bowel syndrome and probiotics: from rationale to clinical use. Curr Opin Gastroenterol 2005, 21:697-701.
157. Verdu E.F., Bercik P., Bergonzelli G.E., Huang X.X., Blennerhasset P., Rochat F., Fiaux M., Mansourian R., Corthesy-Theulaz I., Collins S.M. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004, 127(3):826-837.
158. Verdu E.F., Bercik P., Verma-Gandhu M., Huang X.X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006, 55(2):182-190.
159. Viljanen M., Kuitunen M., Haahtela T., Juntunen-Backman K., Korpela R., Savilahti E. Probiotic effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants. Pediatr Allergy Immunol 2005, 16:65-71.
160. Wang K.Y., Li S.N., Liu C.S., Perng D.S., Su Y.C., Wu D.C., Jan C.M., Lai C.H., Wang T.N., Wang W.M. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr 2004, 80:737-741.
161. Weizman Z., Asli G., Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005, 115:5-9.
162. Wendakoon C.N., Thomson A.B., Ozimek L. Lack of therapeutic effect of a specially designed yogurt for the eradication of Helicobacter pylori infection. Digestion 2002, 65(1):16-20.
163. Wullt M., Hagslatt M.L., Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003, 35:365-367.
164. Yamaguchi D.J., Yan F., Polk D.B. Probiotic Lactobacillus rhamnosus GG stimulates proliferation during intestinal epithelial cell would repair. J Pediatr Gastroenterol Nutr 2003, 37:395.
165. Zoppi G., Cinquetti M., Luciano A., Benini A., Muner A., Bertazzoni Minelli E. The intestinal ecosystem in chronic functional constipation. Acta Paediatr 1998, 87(8):836-841.